Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.05
-1.0%
$2.16
$1.62
$14.67
$6.09M1884,702 shs73,406 shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.59
-0.1%
$0.64
$0.53
$4.41
$24.66M-0.74481,305 shs996,183 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.98
+0.4%
$3.55
$2.57
$6.88
$24.59M0.642,828 shs1,379 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.91
+1.9%
$1.89
$1.35
$53.79
$23.30MN/A176,718 shs91,910 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-0.97%0.00%-8.07%-6.82%-66.68%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-0.05%+2.63%-11.09%-27.33%-62.75%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-0.03%+3.52%+8.90%+18.66%-27.73%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+1.87%-3.05%-18.38%+17.90%-95.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.3632 of 5 stars
0.04.00.00.01.90.00.0
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
2.7271 of 5 stars
3.63.00.00.01.12.50.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.5448 of 5 stars
3.14.00.00.01.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.20
Buy$13.002,108.63% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17537.00% Upside

Current Analyst Ratings Breakdown

Latest ENSC, QTTB, FBLG, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $12.00
8/4/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
7/29/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
7/9/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/17/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.21M1.17N/AN/A$1.03 per share1.99
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.02 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.22N/AN/A$13.32 per share0.30
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.16M20.09N/AN/A($1.00) per share-1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$7.99M-$4.03N/AN/AN/A-88.76%-167.23%-104.59%11/11/2025 (Estimated)
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$11.16M-$0.360.00N/AN/AN/A-710.25%-118.02%11/11/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.300.00N/AN/AN/A-2,709.70%-61.16%11/6/2025 (Estimated)

Latest ENSC, QTTB, FBLG, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$1.02-$0.79+$0.23-$0.79$0.67 million$1.37 million
8/6/2025Q2 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.14-$0.78+$0.36-$0.78N/AN/A
7/31/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.11-$0.12-$0.01-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
2.10
2.10
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
0.93
0.93
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
5.06
5.06

Institutional Ownership

CompanyInstitutional Ownership
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%

Insider Ownership

CompanyInsider Ownership
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
7.90%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
20.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.97 million2.73 millionNot Optionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1041.89 million33.51 millionN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A

Recent News About These Companies

Q32 Bio Inc. (NASDAQ:QTTB) Sees Significant Decline in Short Interest
Q32 Bio (QTTB) Projected to Post Earnings on Thursday
Q32 Bio (QTTB) Q2 Loss Drops 45%
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
Q32 Bio: Q4 Earnings Snapshot
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.05 -0.02 (-0.97%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.08 +0.03 (+1.46%)
As of 08/22/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.59 0.00 (-0.05%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$0.60 +0.01 (+1.09%)
As of 08/22/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.95 -0.01 (-0.23%)
As of 08/22/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.91 +0.04 (+1.87%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.89 -0.02 (-1.05%)
As of 08/22/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.